You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Guidelines & Advice
About Guidelines Email Guidelines Team

The Role of High Dose Rate Brachytherapy in the Palliation of Symptom in Patients with Non-Small Cell Lung Cancer

Version: 4 ID: 7-16 Dec 2022
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
Lung Cancer Disease Site Group

Patient Population

Adult patients with symptomatic endobronchial disease in non-small cell lung cancer.

Research Question(s)

  1. Is there a role for high dose rate endobronchial brachytherapy (HDREB) in the palliation of respiratory symptoms in patients with non-small cell lung cancer?
  2. If so, what is the optimal dose of HDREB in this setting?
pdf download Summary (PDF) (198.14 KB)
pdf download Full Report (PDF) (1.36 MB)